PYC.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 04:28):

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia...

Stats
Dagens volum	1.93M
Gjennomsnittsvolum	1.82M
Markedsverdi	497.87M
EPS	$0 ( 2024-02-25 )
Neste inntjeningsdato	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.00
ATR14	$0.00100 (0.91%)

Volum Korrelasjon

Lang: -0.12 (neutral)

Kort: 0.37 (neutral)

Signal:(67.168) Neutral

PYC Therapeutics Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

PYC Therapeutics Ltd Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.79
( moderate negative )

0.00
( neutral )

0.27
( neutral )

PYC Therapeutics Ltd Økonomi

Annual	2023
Omsetning:	$15.81M
Bruttogevinst:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Omsetning:	$15.81M
Bruttogevinst:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2022
Omsetning:	$16.04M
Bruttogevinst:	$15.20M (94.77 %)
EPS:	$-0.00430

Financial Reports:

No articles found.

PYC Therapeutics Ltd

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.